tirzepatide for kidney disease (Zepbound) showed improved function in obese patients with both chronic kidney and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide Associated with Lower Risk

Shift Costs to Employees Through Higher Copays or Coinsurance Employers can impose higher cost-sharing for GLP-1 drugsplacing them in specialty tiers with copays of ninety dollars or more per prescription, or requiring coinsurance of twenty to thirty percent

[DOI] [PubMed] [Google Scholar] 176.Wong C.Y., Al-Salami H., Dass C.R

Building on these data, here we assess whether the metabolic effects of such an incretin-conjugated PPAR agonist could further be enhanced by covalent tethering of Tesa to the peptide backbone of the DPP4-protected GLP-1RGIPR co-agonist MAR709 32 (Extended Data Fig

Conner Mertens 17:48 Youre welcome back anytime, folks

However, this is not to say that prescribers have never ordered tirzepatide for those with Type I diabetes

Gupta V